1887

Abstract

complex comprises three closely related species, , and . In the last decade, antifungal resistance to azoles and caspofungin among strains has been considered a matter of concern worldwide. In the present study, we evaluated the synergistic potential of antifungals and the calcineurin inhibitor cyclosporin A (Cys) against planktonic and biofilms of complex from clinical sources. Susceptibility assays with amphotericin, fluconazole, voriconazole, caspofungin and Cys were performed by microdilution in accordance with Clinical and Laboratory Standards Institute guidelines. Synergy testing against planktonic cells of strains was assessed by the chequerboard method. Combinations formed by antifungals with Cys were evaluated against mature biofilms in microtitre plates. No differences in the antifungal susceptibility pattern among species were observed, but strains were more susceptible to Cys than and Synergism between antifungals and Cys was observed in strains. Combinations formed by antifungals and Cys were able to prevent biofilm formation and showed an inhibitory effect against mature biofilms of , and These results strengthen the potential of calcineurin inhibition as a promising approach to enhance the efficiency of antifungal drugs.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.073478-0
2014-07-01
2022-01-29
Loading full text...

Full text loading...

/deliver/fulltext/jmm/63/7/936.html?itemId=/content/journal/jmm/10.1099/jmm.0.073478-0&mimeType=html&fmt=ahah

References

  1. Almirante B., Rodríguez D., Cuenca-Estrella M., Almela M., Sanchez F., Ayats J., Alonso-Tarres C., Rodriguez-Tudela J. L., Pahissa A. 2006; Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 44:1681–1685 [View Article][PubMed]
    [Google Scholar]
  2. Bassetti M., Taramasso L., Nicco E., Molinari M. P., Mussap M., Viscoli C. 2011; Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS ONE 6:e24198 [View Article][PubMed]
    [Google Scholar]
  3. Bonfietti L. X., Martins M. dos A., Szeszs M. W., Pukiskas S. B., Purisco S. U., Pimentel F. C., Pereira G. H., Silva D. C., Oliveira L., Melhem M. S. 2012a; Prevalence, distribution and antifungal susceptibility profiles of Candida parapsilosis, Candida orthopsilosis and Candida metapsilosis bloodstream isolates. J Med Microbiol 61:1003–1008 [View Article][PubMed]
    [Google Scholar]
  4. Bonfietti L. X., Szeszs M. W., Chang M. R., Martins M. A., Pukinskas S. R., Nunes M. O., Pereira G. H., Paniago A. M., Purisco S. U., Melhem M. S. 2012b; Ten-year study of species distribution and antifungal susceptibilities of Candida bloodstream isolates at a Brazilian tertiary hospital. Mycopathologia 174:389–396 [View Article][PubMed]
    [Google Scholar]
  5. Cantón E., Espinel-Ingroff A., Pemán J., del Castillo L. 2010; In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. Antimicrob Agents Chemother 54:2194–2197 [View Article][PubMed]
    [Google Scholar]
  6. Cantón E., Pemán J., Quindós G., Eraso E., Miranda-Zapico I., Álvarez M., Merino P., Campos-Herrero I., Marco F.& other authors ( 2011; Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia. Antimicrob Agents Chemother 55:5590–5596 [View Article][PubMed]
    [Google Scholar]
  7. Chandra J., Mukherjee P. K., Ghannoum M. A. 2012; Candida biofilms associated with CVC and medical devices. Mycoses 55:46–57 [View Article]
    [Google Scholar]
  8. Chen Y. C., Lin Y. H., Chen K. W., Lii J., Teng H. J., Li S. Y. 2010; Molecular epidemiology and antifungal susceptibility of Candida parapsilosis sensu stricto, Candida orthopsilosis, and Candida metapsilosis in Taiwan. Diagn Microbiol Infect Dis 68:284–292 [View Article][PubMed]
    [Google Scholar]
  9. Chen Y. L., Brand A., Morrison E. L., Silao F. G. S., Bigol U. G., Malbas F. F. Jr, Nett J. E., Andes D. R., Solis N. V.& other authors ( 2011; Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis. Eukaryot Cell 10:803–819 [View Article][PubMed]
    [Google Scholar]
  10. Chong P. P., Abdul Hadi S. R., Lee Y. L., Phan C. L., Tan B. C., Ng K. P., Seow H. F. 2007; Genotyping and drug resistance profile of Candida spp. in recurrent and one-off vaginitis, and high association of non-albicans species with non-pregnant status. Infect Genet Evol 7:449–456 [View Article][PubMed]
    [Google Scholar]
  11. CLSI 2008 Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts Approved standard M27-A Wayne, PA: Clinical and Laboratory Standards Institute (formerly National Committee for Clinical Laboratory Standards);
    [Google Scholar]
  12. Colombo A. L., Nucci M., Park B. J., Nouér S. A., Arthington-Skaggs B., da Matta D. A., Warnock D., Morgan J.Brazilian Network Candidemia Study 2006; Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 44:2816–2823 [View Article][PubMed]
    [Google Scholar]
  13. Costa S. F., Marinho I., Araújo E. A. S., Manrique A. E. I., Medeiros E. A. S., Levin A. S. 2000; Nosocomial fungaemia: a 2-year prospective study. J Hosp Infect 45:69–72 [View Article][PubMed]
    [Google Scholar]
  14. De Hoog G. S., Guarro J., Gené J., Figueras M. J. 2000 Atlas of Clinical Fungi, 2nd edn. Spain: Centralalbureau voor Schimmelcultures/Universitat Rovira I Virgili Reus;
    [Google Scholar]
  15. Del Poeta M., Cruz M. C., Cardenas M. E., Perfect J. R., Heitman J. 2000; Synergistic antifungal activities of bafilomycin A1, fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother 44:739–746 [View Article][PubMed]
    [Google Scholar]
  16. Falagas M. E., Roussos N., Vardakas K. Z. 2010; Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis 14:e954–e966 [View Article][PubMed]
    [Google Scholar]
  17. Gácser A., Schäfer W., Nosanchuk J. S., Salomon S., Nosanchuk J. D. 2007; Virulence of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis in reconstituted human tissue models. Fungal Genet Biol 44:1336–1341 [View Article][PubMed]
    [Google Scholar]
  18. Garcia-Effron G., Santosh K. K., Park S., Edlind T. D., Perlin D. S. 2008; A naturally occurring proline-to-alanine amino acid change in fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 52:2305–2312 [View Article][PubMed]
    [Google Scholar]
  19. Garcia-Effron G., Canton E., Pemán J., Dilger A., Romá E., Perlin D. S. 2012; Epidemiology and echinocandin susceptibility of Candida parapsilosis sensu lato species isolated from bloodstream infections at a Spanish university hospital. J Antimicrob Chemother 67:2739–2748 [View Article][PubMed]
    [Google Scholar]
  20. Godoy P., Tiraboschi I. N., Severo L. C., Bustamante B., Calvo B., Almeida L. P., da Matta D. A., Colombo A. L. 2003; Species distribution and antifungal susceptibility profile of Candida spp. bloodstream isolates from Latin American hospitals. Mem Inst Oswaldo Cruz 98:401–405 [View Article][PubMed]
    [Google Scholar]
  21. Legout L., Assal M., Rohner P., Lew D., Bernard L., Hoffmeyer P. 2006; Successful treatment of Candida parapsilosis (fluconazole-resistant) osteomyelitis with caspofungin in a HIV patient. Scand J Infect Dis 38:728–730 [View Article][PubMed]
    [Google Scholar]
  22. Li Y., Sun S., Guo Q., Ma L., Shi C., Su L., Li H. 2008; In vitro interaction between azoles and cyclosporin A against clinical isolates of Candida albicans determined by the chequerboard method and time-kill curves. J Antimicrob Chemother 61:577–585 [View Article][PubMed]
    [Google Scholar]
  23. Lockhart S. R., Messer S. A., Pfaller M. A., Diekema D. J. 2008; Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis.. J Clin Microbiol 46:2659–2664 [View Article][PubMed]
    [Google Scholar]
  24. Marchetti O., Moreillon P., Glauser M. P., Bille J., Sanglard D. 2000; Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans.. Antimicrob Agents Chemother 44:2373–2381 [View Article][PubMed]
    [Google Scholar]
  25. Medrano D. J. A., Brilhante R. S. N., Cordeiro R. A., Rocha M. F., Rabenhorst S. H. B., Sidrim J. J. C. 2006; Candidemia in a Brazilian hospital: the importance of Candida parapsilosis. Rev Inst Med Trop Sao Paulo 48:17–20 [View Article][PubMed]
    [Google Scholar]
  26. Melo A. S., Bizerra F. C., Freymüller E., Arthington-Skaggs B. A., Colombo A. L. 2011; Biofilm production and evaluation of antifungal susceptibility amongst clinical Candida spp. isolates, including strains of the Candida parapsilosis complex. Med Mycol 49:253–262 [View Article][PubMed]
    [Google Scholar]
  27. Miranda L., Rodrigues E. C., Costa S. F., van der Heijden I. M., Dantas K. C., Lobo R. D., Basso M., Varkulja G. F., Krebs V. L.& other authors ( 2012; Candida parapsilosis candidaemia in a neonatal unit over 7 years: a case series study. BMJ Open 2:e000992 [View Article][PubMed]
    [Google Scholar]
  28. Moudgal V., Little T., Boikov D., Vazquez J. A. 2005; Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 49:767–769 [View Article][PubMed]
    [Google Scholar]
  29. Nosek J., Holesova Z., Kosa P., Gacser A., Tomaska L. 2009; Biology and genetics of the pathogenic yeast Candida parapsilosis. Curr Genet 55:497–509 [View Article][PubMed]
    [Google Scholar]
  30. Nucci M., Queiroz-Telles F., Tobón A. M., Restrepo A., Colombo A. L. 2010; Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis 51:561–570 [View Article][PubMed]
    [Google Scholar]
  31. Odds F. C. 2003; Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52:1 [View Article][PubMed]
    [Google Scholar]
  32. Orsi C. F., Colombari B., Blasi E. 2010; Candida metapsilosis as the least virulent member of the ‘C. parapsilosis’ complex. Med Mycol 48:1024–1033 [View Article][PubMed]
    [Google Scholar]
  33. Pammi M., Holland L., Butler G., Gacser A., Bliss J. M. 2013; Candida parapsilosis is a significant neonatal pathogen: a systematic review and meta-analysis. Pediatr Infect Dis J 32:e206–e216 [View Article][PubMed]
    [Google Scholar]
  34. Pereira G. H., Müller P. R., Szeszs M. W., Levin A. S. C., Melhem M. S. C. 2010; Five-year evaluation of bloodstream yeast infections in a tertiary hospital: the predominance of non-C. albicans Candida species. Med Mycol 48:839–842 [View Article][PubMed]
    [Google Scholar]
  35. Pfaller M. A., Diekema D. J. 2007; Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133–163 [View Article][PubMed]
    [Google Scholar]
  36. Pfaller M. A., Diekema D. J., Gibbs D. L., Newell V. A., Ng K. P., Colombo A., Finquelievich J., Barnes R., Wadula J.Global Antifungal Surveillance Group 2008; Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 46:842–849 [View Article][PubMed]
    [Google Scholar]
  37. Pires R. H., Santos J. M., Zaia J. E., Martins C. H., Mendes-Giannini M. J. 2011; Candida parapsilosis complex water isolates from a haemodialysis unit: biofilm production and in vitro evaluation of the use of clinical antifungals. Mem Inst Oswaldo Cruz 106:646–654 [View Article][PubMed]
    [Google Scholar]
  38. Ruiz L. S., Khouri S., Hahn R. C., da Silva E. G., de Oliveira V. K. P., Gandra R. F., Paula C. R. 2013; Candidemia by species of the Candida parapsilosis complex in children’s hospital: prevalence, biofilm production and antifungal susceptibility. Mycopathologia 175:231–239 [View Article][PubMed]
    [Google Scholar]
  39. Sardi J. C. O., Scorzoni L., Bernardi T., Fusco-Almeida A. M., Mendes Giannini M. J. 2013; Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol 62:10–24 [View Article][PubMed]
    [Google Scholar]
  40. Sarvikivi E., Lyytikäinen O., Soll D. R., Pujol C., Pfaller M. A., Richardson M., Koukila-Kähkölä P., Luukkainen P., Saxén H. 2005; Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol 43:2729–2735 [View Article][PubMed]
    [Google Scholar]
  41. Seneviratne C. J., Jin L., Samaranayake L. P. 2008; Biofilm lifestyle of Candida: a mini review. Oral Dis 14:582–590 [View Article][PubMed]
    [Google Scholar]
  42. Shinde R. B., Chauhan N. M., Raut J. S., Karuppayil S. M. 2012; Sensitization of Candida albicans biofilms to various antifungal drugs by cyclosporine A. Ann Clin Microbiol Antimicrob 11:27 [View Article][PubMed]
    [Google Scholar]
  43. Shirazi F., Kontoyiannis D. P. 2013; The calcineurin pathway inhibitor tacrolimus enhances the in vitro activity of azoles against Mucorales via apoptosis. Eukaryot Cell 12:1225–1234 [View Article][PubMed]
    [Google Scholar]
  44. Sidrim J. J. C., Perdigão-Neto L. V., Cordeiro R. A., Brilhante R. S. N., Teixeira C. E. C., Castelo-Branco D. S. C. M., Costa A. K. F., Araújo R. M. C., Mesquita J. R.& other authors ( 2011; Candida parapsilosis meningitis as the first manifestation of AIDS: case report. J Med Microbiol 60:1530–1533 [View Article][PubMed]
    [Google Scholar]
  45. Silva A. P., Miranda I. M., Lisboa C., Pina-Vaz C., Rodrigues A. G. 2009; Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital. J Clin Microbiol 47:2392–2397 [View Article][PubMed]
    [Google Scholar]
  46. Song J. W., Shin J. H., Shint D. H., Jung S. I., Cho D., Kee S. J., Shin M. G., Suh S. P., Ryang D. W. 2005; Differences in biofilm production by three genotypes of Candida parapsilosis from clinical sources. Med Mycol 43:657–661 [View Article][PubMed]
    [Google Scholar]
  47. Spreghini E., Orlando F., Tavanti A., Senesi S., Giannini D., Manso E., Barchiesi F. 2012; In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis.. J Antimicrob Chemother 67:2195–2202 [View Article][PubMed]
    [Google Scholar]
  48. Steinbach W. J., Singh N., Miller J. L., Benjamin D. K. Jr, Schell W. A., Heitman J., Perfect J. R. 2004; In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. Antimicrob Agents Chemother 48:4922–4925 [View Article][PubMed]
    [Google Scholar]
  49. Tavanti A., Davidson A. D., Gow N. A. R., Maiden M. C. J., Odds F. C. 2005; Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 43:284–292 [View Article][PubMed]
    [Google Scholar]
  50. Toro M., Torres M. J., Maite R., Aznar J. 2011; Characterization of Candida parapsilosis complex isolates. Clin Microbiol Infect 17:418–424 [View Article][PubMed]
    [Google Scholar]
  51. Trofa D., Gácser A., Nosanchuk J. D. 2008; Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 21:606–625 [View Article][PubMed]
    [Google Scholar]
  52. Uppuluri P., Nett J., Heitman J., Andes D. 2008; Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother 52:1127–1132 [View Article][PubMed]
    [Google Scholar]
  53. van Asbeck E. C., Clemons K. V., Stevens D. A. 2009; Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility. Crit Rev Microbiol 35:283–309 [View Article][PubMed]
    [Google Scholar]
  54. Zhang J., Silao F. G. S., Bigol U. G., Bungay A. A. C., Nicolas M. G., Heitman J., Chen Y. L. 2012; Calcineurin is required for pseudohyphal growth, virulence, and drug resistance in Candida lusitaniae.. PLoS ONE 7:e44192 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.073478-0
Loading
/content/journal/jmm/10.1099/jmm.0.073478-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error